• Sales USD 331 million
  • Gradual increase in sales during the year
  • EBITDA margin 20%
  • Strong performance in Prosthetics
  • Second generation of Bionics launched
  • Enhanced sales platform in place
  • Listing on NASDAQ OMX Copenhagen

Guidance 2010: 

  • Sales 3-4% LCY growth
  • EBITDA 8-10% LCY growth


Jon Sigurdsson, President & CEO, comments: 
“The results for 2009 are good and show clearly the Company’s strength. During the year we have seen the global economic turmoil having an impact on our customers and affecting some of our markets. However, Össur continues to be profitable and operations are sound. Our Bionic product line has gained further momentum through the launch of the second generation of the RHEO KNEE as well as the acceptance of the PROPRIO FOOT into the US reimbursement systems. In 2009 we have invested significantly in aligning our B&S business to take advantage of the prevailing market opportunity. We believe that 2010 will be an exciting year for Össur.” 

  Financial Statements 2009 (319 kb)      Investor Presentation (1,3 mb)      Q4 2009 (337 kb)     
Recent Posts